Evidence map›Paper›PMID 26335347›Full record

ArticlePloS one2015

Comparative Incidence of Conformational, Neurodegenerative Disorders.

Jesús de Pedro-Cuesta, Alberto Rábano, Pablo Martínez-Martín, María Ruiz-Tovar, Enrique Alcalde-Cabero, Javier Almazán-Isla, Fuencisla Avellanal, Miguel Calero

Erratum issuedAbstract readComparative Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jesús de Pedro-CuestaDepartment of Applied Epidemiology, CNE, National Institute of Health Carlos III, Madrid, Spain; Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), National Institute of Health Carlos III, Madrid, Spain.
Alberto RábanoAlzheimer's Disease Centre, Reina Sofia Foundation, Madrid, Spain.
Pablo Martínez-MartínDepartment of Applied Epidemiology, CNE, National Institute of Health Carlos III, Madrid, Spain; Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), National Institute of Health Carlos III, Madrid, Spain.
María Ruiz-TovarDepartment of Applied Epidemiology, CNE, National Institute of Health Carlos III, Madrid, Spain; Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), National Institute of Health Carlos III, Madrid, Spain.
Enrique Alcalde-CaberoDepartment of Applied Epidemiology, CNE, National Institute of Health Carlos III, Madrid, Spain; Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), National Institute of Health Carlos III, Madrid, Spain.
Javier Almazán-IslaDepartment of Applied Epidemiology, CNE, National Institute of Health Carlos III, Madrid, Spain; Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), National Institute of Health Carlos III, Madrid, Spain.
Fuencisla AvellanalDepartment of Applied Epidemiology, CNE, National Institute of Health Carlos III, Madrid, Spain; Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), National Institute of Health Carlos III, Madrid, Spain.
Miguel CaleroAlzheimer's Disease Centre, Reina Sofia Foundation, Madrid, Spain; CIBERNED, National Institute of Health Carlos III, Majadahonda, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to identify incidence and survival patterns in conformational neurodegenerative disorders (CNDDs).

methodsWe identified 2563 reports on the incidence of eight conditions representing sporadic, acquired and genetic, protein-associated, i.e., conformational, NDD groups and age-related macular degeneration (AMD). We selected 245 papers for full-text examination and application of quality criteria. Additionally, data-collection was completed with detailed information from British, Swedish, and Spanish registries on Creutzfeldt-Jakob disease (CJD) forms, amyotrophic lateral sclerosis (ALS), and sporadic rapidly progressing neurodegenerative dementia (sRPNDd). For each condition, age-specific incidence curves, age-adjusted figures, and reported or calculated median survival were plotted and examined.

findingsBased on 51 valid reported and seven new incidence data sets, nine out of eleven conditions shared specific features. Age-adjusted incidence per million person-years increased from ≤1.5 for sRPNDd, different CJD forms and Huntington's disease (HD), to 1589 and 2589 for AMD and Alzheimer's disease (AD) respectively. Age-specific profiles varied from (a) symmetrical, inverted V-shaped curves for low incidences to (b) those increasing with age for late-life sporadic CNDDs and for sRPNDd, with (c) a suggested, intermediate, non-symmetrical inverted V-shape for fronto-temporal dementia and Parkinson's disease. Frequently, peak age-specific incidences from 20-24 to ≥90 years increased with age at onset and survival. Distinct patterns were seen: for HD, with a low incidence, levelling off at middle age, and long median survival, 20 years; and for sRPNDd which displayed the lowest incidence, increasing with age, and a short median disease duration.

interpretationThese results call for a unified population view of NDDs, with an age-at-onset-related pattern for acquired and sporadic CNDDs. The pattern linking age at onset to incidence magnitude and survival might be explained by differential pathophysiological mechanisms associated with specific misfolded protein deposits.

Indexed as

AdolescentAdultAgedAged, 80 and overAge DistributionAge of OnsetChildChild, PreschoolEuropeFemaleHumansIncidenceInfantInfant, NewbornMacular DegenerationMalePrions

Identifiers

PMID26335347
PMCPMC4559310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.